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Next-generation sequencing of 
common osteogenesis imperfecta-
related genes in clinical practice
Kristóf Árvai1,2,*, Péter Horváth1,*, Bernadett Balla1,2, Bálint Tobiás1,2, Karina Kató1,2, 
Gyöngyi Kirschner1, Valéria Klujber2, Péter Lakatos1,2,* & János P. Kósa1,2,*
Next generation sequencing (NGS) is a rapidly developing area in genetics. Utilizing this technology 
in the management of disorders with complex genetic background and not recurrent mutation hot 
spots can be extremely useful. In this study, we applied NGS, namely semiconductor sequencing to 
determine the most significant osteogenesis imperfecta-related genetic variants in the clinical practice. 
We selected genes coding collagen type I alpha-1 and-2 (COL1A1, COL1A2) which are responsible for 
more than 90% of all cases. CRTAP and LEPRE1/P3H1 genes involved in the background of the recessive 
forms with relatively high frequency (type VII and VIII) represent less than 10% of the disease. In our 
six patients (1–41 years), we identified 23 different variants. We found a total of 14 single nucleotide 
variants (SNV) in COL1A1 and COL1A2, 5 in CRTAP and 4 in LEPRE1. Two novel and two already well-
established pathogenic SNVs have been identified. Among the newly recognized mutations, one results 
in an amino acid change and one of them is a stop codon. We have shown that a new full-scale cost-
effective NGS method can be developed and utilized to supplement diagnostic process of osteogenesis 
imperfecta with molecular genetic data in clinical practice.
With the appearance of next generation sequencing (NGS) machines, molecular biology has entered in a new 
revolutionary phase. These new techniques combine high performance with much less expensive operation costs1. 
Thanks to the new benchtop sequencers, every laboratory has the opportunity to utilize next generation sequenc-
ing either as a research or a diagnostic tool. There is a variety of different methods in next generation sequencing. 
There is pyrosequencing, fluorescent detection of dNTP incorporation and last but not least semi-conductor 
sequencing technology2. Former sequencing systems used irreversible dye terminators of nucleic acid sequencing, 
as described by Sanger et al. all four terminators having different dyes3. This is the “gold standard” method, how-
ever, it is not only expensive but also a very time-consuming procedure. Next generation sequencing creates sig-
nals during the synthesis without the irreversible termination of the DNA strand, and all strands run in multiple 
wells at the same time. Therefore, the sequencing is massively paralleled, it could mean millions of DNA strands 
sequenced at once, thus giving much more information in much less time.
Our aim was to work out a NGS method utilizing the IonTorrent PGM (ThermoFisher Scientific, Waltham, 
MA, USA) in diagnostic settings for osteogenesis imperfecta (OI). Osteogenesis imperfecta or brittle bone disease 
is a rare genetic disorder - with dominant or recessive inheritance pattern-of the skeletal system. The background 
of the disease in most cases is a mutation of the genes encoding collagen type I molecule complex4. In a smaller, 
but significant number of cases the disease is caused by variants in other genes related to collagen synthesis5,6. 
Type I collagen is a commonly found protein in the body: it is in the walls of the viscera and the vessels, in the 
skin and in the bone tissue7. Bone has two parts: the organic part, which is the matrix synthesized by bone cells or 
osteoblasts, and the inorganic part, which means calcium salts deposited in the matrix8. In osteogenesis imper-
fecta, the corrupted collagen cannot form the appropriate matrix which leads to a brittle, fragile skeletal system9.
Type I collagen has a helical structure. It is built up by two strands of alpha-1 protein and one strand of alpha-2 
protein. Alpha-1 is encoded by COL1A1, alpha-2 is encoded by COL1A210. These genes have a relatively high 
number of exons, which makes them complicated to sequence by conventional methods. Both COL1A1 and 
COL1A2 contain 52 exons11. In addition, no dramatic mutation ‘hot spots’ have been identified within these 
11st Department of Internal Medicine, Semmelweis University, H-1083 Budapest, Korányi S. u. 2/a, Hungary. 
2PentaCore Laboratory, H-1094 Budapest, Bokréta u. 5, Hungary. *These authors contributed equally to this work. 
Correspondence and requests for materials should be addressed to K.Á. (email: Kristof.arvai@gmail.com)
received: 18 February 2016
accepted: 24 May 2016
Published: 23 June 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:28417 | DOI: 10.1038/srep28417
genes. Because of this, almost 2,500 different COL1A1 and COL1A2 mutations have been reported and listed in 
the Osteogenesis Imperfecta Variant Database (http://www.le.ac.uk/ge/collagen/).
First, this disease was believed to be caused by the mutation of these two genes and OI had four categories 
(Sillence Classificaton), however, it turned out that Type IV has several different subtypes. Among these sub-
types, there are cases where OI is caused by the variations of the proteins that facilitate the appropriate folding 
of type I collagen11–16. Microscopic studies of OI bone identified people who are clinically within Type IV group 
but have distinctive patterns to their bone. As a result of this research, Type V and VI were added to the Sillence 
Classification. Two recessive types of OI, Types VII and VIII, were identified in 2006. Unlike the dominantly 
inherited types, the recessive types of OI do not involve mutations in the type I collagen genes. These recessive 
types of OI result from mutations in the cartilage-associated protein gene (CRTAP) and the prolyl 3-hydroxylase 
1 gene (LEPRE1/P3H1) genes17,18. In the past years, recessive OI types due to very rare defects in additional genes 
(e.g. PEDF, HSP47, FKBP65 and BMP-1) have been described in the literature6,19. Different types of OI could 
have similar clinical features, thus, the definitive diagnosis can be revealed by analyses of the genes lying in the 
background of the disease.
Results
Descriptive results from sequencing runs. After chip loading, the Ion Sphere Particles (ISPs) density was 
between 64–87% (average: 77.66%). Average number of total reads was 2.842.181 (range: 1.714.250–3.506.477). 
Average number of reads on target was 436.086. Average target coverage 1x was 98.65% with a raw mean accuracy 
of 99.03%. The average base coverage depth was 779 (118–1769). In the six patients, we identified 23 different 
variations (Table 1). We found 7 in COL1A1 and 7 in COL1A2.
We have identified three novel variations. Two of them, namely c.189C > A (COL1A1) and c.811G > T 
(COL1A2) are considered as pathogenic. Variant c.189C > A is located in exon 2 of the COL1A1 gene. The variant 
causes premature termination of translation and nonsense mediated decay of the mRNA as it is a stop codon 
mutation. The c.811 G > T: p.Gly271Cys is positioned in COL1A2. Position c.811 in exon 17 was previously rec-
ognized as a locus for pathogenic variant (G > C substitution, causing a glycine > arginine amino acid change), 
however, no G > T substitution was ever described. This G > T transversion results in a glycin > cysteine change 
at amino acid level. Prediction softwares PolyPhen-2 and SIFT classify both alteration in the same deleterious 
or damaging category. In case of both G > C and G > T nucleotide substitution, the uncharged, apolar glycine is 
switched to charged amino acids with polar side chains. The targeted checking of c.811G > T variant was carried 
out and we detected it in the affected family members showing OI phenotype.
Gene ID dbSNP Coding variant Protein effect Variant type MAF
COL1A1 N/A c.189C > A† p.Cys63Ter pathogenic N/A
COL1A1 N/A c.391C > T p.Arg131Ter pathogenic N/A
COL1A1 N/A c.750 + 1G > A Splice site pathogenic N/A
COL1A1 N/A c.2427C > G p.(= ).Gly809 synonym variant N/A
COL1A1 rs17857117 c.4313C > G p.Pro1438Arg missense, non-pathogenic N/A
COL1A1 rs1800215 c.3223A > G p.(= ).Ala1075 synonym variant T = 0.0212/106
COL1A1 rs2734272 c.2298T > C p.(= ).Thr766 synonym variant A = 0.0002/1
COL1A2 N/A c.2072G > A† p.Gly691Asp VUS N/A
COL1A2 N/A c.811G > T† p.Gly271Cys pathogenic N/A
COL1A2 rs1800222 c.246T > C p.(= ).Asp82 synonym variant C = 0.312/682
COL1A2 rs1800248 c.3135C > T p.(= ).Gly1045 synonym variant T = 0.089/195
COL1A2 rs42519 c.937-3C > T Splice site intronic C = 0.145/317
COL1A2 rs42524 c.1645C > G p.Pro549Ala missense, non-pathogenic C = 0.147/321
COL1A2 rs412777 c.1446A > C p.(= )Pro482 synonym variant C = 0.3273/1639
CRTAP rs1135127 c.1032T > G p.(= ).Thr344 synonym variant G = 0.281/614
CRTAP rs1135128 c.1044G > A p.(= ).Ser348 synonym variant A = 0.281/614
CRTAP rs11558338 c.213G > A p.(= ).Leu71 synonym variant A = 0.260/568
CRTAP rs4076086 c.534C > T p.(= ).Asp178 synonym variant T = 0.300/656
CRTAP rs145048208 c.655G > A p.Gly219Ser missense variant N/A
LEPRE1 rs3738496 c.2129T > A p.Phe710Tyr common missense variant T = 0.141/308
LEPRE1 rs4660662 c.2148T > C p.(= ).Gly716 synonym variant N/A
LEPRE1 rs116577636 c.2248G > A p.Gly750Arg missense variant T = 0.0012/6
LEPRE1 rs11581921 c.1647G > A p.Met549Ile common missense variant T = 0.0575/288
Table 1.  List of variants in six patients sorted by genes. It is clearly visible that the most polymorphic genes 
are COL1A1 and COL1A2. The most of the pathogenic variants were found in COL1A1. The † symbol marks 
the newly identified variants. Position c.811G > T is a known locus for pathogenic variants, however no 
guanine > thymine change was previously described. MAF: minor allele frequency from dbSNP database, N/A: 
not available.
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We have found a variant, namely c.2072G > A: p.Gly691Asp which is located in the coding sequence of exon 
31 of COL1A2. According to the applied prediction softwares, this variant damages the protein structure. The 
presented G > A transition results in a glycine to aspartic acid alteration. Collection of segregation data in the 
presence of this variant was not available, thus, we considered it as a variant with uncertain significance (VUS).
Furthermore, we have also described two already established pathogenic variants, c.391C > T (COL1A1) and 
c.750+ 1G > A (COL1A1). The c.391C > T substitution causes a stop codon (p.Arg131Ter) in exon 5. The other 
mutation, c.750+ 1G > A is a splice site variant in intron 10.
All of the called variants with clinical significance were validated by Sanger sequencing. No false positive 
samples were seen in the Ion Torrent reads.
Results of the individual patients. We enrolled 6 patients in our study, four males and two females. Age 
range was between 1–41 years. Bone mineral density (BMD) was measured at the lumbar spine in participants 
and decreased BMD were detected compared to the normal age-matched values. Detailed patients’ information 
can be found in Table 2.
Discussion
We were among the first who apply NGS technology to analyze osteogenesis imperfecta-related genes in 
clinical settings. In this study, we attempted to demonstrate the huge potential of NGS in the clinical practice of 
OI affected patients. In most of the cases, genetic results support the accurate diagnosis as well as significantly 
contribute to the subclassification of OI, especially in mild phenotypes.
Osteogenesis Imperfecta Variant Database contains genetic variants from 19 genes (http://www.le.ac.uk/ge/
collagen/). We decided to target four of them (COL1A1, COL1A2, CRTAP, LEPRE1/P3H1) because genes coding 
collagen type I alpha-1 and -2 chains are responsible for more than 90% of all cases4,20. Genes involved in the 
background of the recessive forms with relatively high frequency (type VII and VIII) represent less than 10% of 
the disease19.
Genes related to OI usually contain numerous coding exons (total 126 exons of 4 genes in our study). The 
large number of the targeted genomic regions and the lack of mutation hot spots, resulting in a very time- and 
cost-demanding molecular analysis when diagnosis is set up by classic Sanger sequencing. Wang et al. demon-
strated the efficacy of high resolution melting (HRM) analysis of COL1A1 and COL1A2 genes in OI subjects21. 
This is a pre-screening technology, therefore, every identified genetic variant needs to be confirmed by Sanger 
sequencing. In contrast, using NGS, the verification is necessary only for the pathogenic mutations. Sule et al. also 
presented the accuracy of NGS platform in patients with various disorders of low and high bone mineral density 
in a clinical setting22.
We have developed our NGS method utilizing IonTorrent PGM from ThermoFisher Scientific. This benchtop 
sequencer belongs to the semiconductor sequencer family. It acquires the DNA sequence by detecting electric 
impulses created by the release of H+-ions in its microchip. The solution which contains the H+-ions serves as a 
gate electrode of a transistor, a so-called ion-sensitive field electricity transistor (ISFET)23. Using this technique, 
we have identified a total of 23 different variants in the selected 4 genes at the same time in a cost-effective 
manner.
When a genetic test panel is created for the clinical practice, it is important, that it contains only 
well-established genes with clear relationship to the disorder24. According to the latest guideline from the 
American College of Medical Genetics and Genomics (ACMG), it is necessary to limit the number of variants 
with uncertain significance (VUS) as low as possible25. The probability to find VUSs is getting higher as the 
targeted areas of the genome are increasing. VUSs can confuse both the clinicians and the patients and can put 
unnecessary burden to the patients shoulder. Moreover, such findings can lower the clinical utility of a genetic 












Patient 1† Male 9 3 0.381 c.391C > T (COL1A1) Father and paternal grandmother has OI Yes N/A
Patient 2 Male 41 10 N/A c.391C > T (COL1A1) Mother has OI No Yes
Patient 3 Male 18 3 0.685 c.2072G > A (COL1A2)‡ No No Yes
Patient 4 Female 2 3 0.390 c.189C > A (COL1A1)
Mother has blue 
sclera, but no 
fractures
Yes N/A
Patient 5 Female 1 3 0.170 c.811G > T (COL1A2) Mother had 7 fractures No No
Patient 6 Male 1 1 0.167 c.750 + 1G > A(COL1A1) No Yes N/A
Table 2.  Patient characteristics and genetic variants with clinical significance in OI. Bone mineral density 
(BMD) was measured at the lumbar spine by dual-energy X-ray absorptiometry (DPX-L, Lunar Corp. Madison, 
WI, USA). * History of recurrent low-energy fractures: Patient 1 had 2 fracture events with 3 fragility fractures 
(tibia, fibula and radius). Patient 2 had approximately 10 fractures. Patient 3 had 3 fracture events with 3 
fragility fractures (skull, clavicular and femoral neck). Patient 4 had 3 fracture events with 3 fragility fractures 
(tibia, femur and humerus). Patient 5 had 3 fracture events with 3 fragility fractures (tibia, femur). Patient 6 
had 1 fracture event with a femoral fracture. †Patient 1 is the son of Patient 2. ‡Variant c.2072G > A (COL1A2) 
classified as VUS.
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pathogenic variants, and a more extended gene panel is required only when the common OI-associated genes are 
intact or the family anamnesis is unclear.
Osteogenesis imperfecta is a perfect example to show NGS potential to be used effectively. It is relatively easy 
to set up the diagnosis of OI but it is really difficult to inevitably identify the causative genetic alteration in each 
patient. Researchers find more and more genes and variations playing role in the development of the disease. In 
our study, we recognized 1 novel variant in the COL1A1 gene and 2 new alterations in COL1A2 gene which are 
not present in current databases.
Mutation c.189C > A in COL1A1 gene causes premature termination of collagen type I alpha-1 chain synthe-
sis. Position c.811 in COL1A2 exon 17 was previously identified as a locus for pathogenic variants, resulting in a 
glycine > arginine change. Our newly determined G > T substitution modified glycine to cysteine at amino acid 
level. This novel alteration is categorized as deleterious. Partly, because cysteine can form disulfide bridges which 
may have a significant impact on the COL1A2 protein conformation by prediction softwares. Moreover, the 
clinical relevance of c.811G > T variation was strengthened by segregation data from family screening. All of the 
affected family member (mother and younger sister) carry this mutation and also show clinical symptoms of OI.
Position c.2072A > G is located in the 31st coding exon of COL1A2 which is a glycine > aspartic acid change 
at protein level, replacing an apolar amino acid to a polar, negatively charged type. According to mutation effect 
prediction algorithms, this variant damages the structure of alpha-2 chain. There is no family history of OI in case 
of this patient, and this variant might be a de novo mutation, however, family screening was not possible. Thus, 
we defined c.2072A > G as a VUS.
Two rare missense variants, namely c.4313C > G in COL1A1 gene and c.655G > A in CRTAP gene were found 
in our cohort. Even though both alterations cause amino acid changes, there is no exact literature data about their 
pathogenicity. Moreover, in each cases they co-occure with a well-defined disease causing mutation (in patient 4 
and in patient 6) Based on this information, we suggest that the identified two rare missense variants should be 
characterized as likely benign.
The exact diagnosis is relevant since it might have an impact on the treatment of the individual, and it is also 
important when it comes to family planning and genetic counseling. In many cases, two healthy parents has an 
OI affected child and it could be mandatory to know if the child has a new de novo mutation or it has the recessive 
inheritance of the disease26. To decide between these questions and to avoid the unnecessary invasive prenatal 
test during the next pregnancy, genetic analysis of the proband utilizing NGS technology can give rapid, compre-
hensive and accurate answer.
In summary, we have shown that a new full-scale cost-effective NGS method can be developed and utilized to 
supplement diagnostic process of osteogenesis imperfecta with molecular genetic data in clinical practice.
Materials and Methods
Biological samples and DNA isolation. Six Caucasian patient samples were selected and anonymized 
for this study. Five patients were unrelated and patient 1 was related to patient 2. DNA was isolated from 200 μ l 
of peripheral blood using Reliaprep Blood gDNA Miniprep System according to the manufacturer’s instruc-
tions (Promega, Fitchburg, WI, USA). The concentration of the isolated DNA was determined by Qubit dsDNA 
HS Assay Kit (ThermoFisher Scientific, Waltham, MA, USA). The study was approved by the Semmelweis 
University’s Committee of Research Ethics, and all patients gave written informed consent. All experiments were 
performed in accordance with relevant guideline and regulation.
Capture design. The target list was carefully prepared based on literature data and the information in NIH 
Genetic Home Reference site (http://ghr.nlm.nih.gov/). We selected four genes for the analysis. Mutations in 
COL1A1 (4395 bp, 52 exons) and COL1A2 (4101 bp, 52 exons) genes are responsible for approximately 90% 
of all OI cases. Mutations in the CRTAP (1206 bp, 7 exons) and LEPRE1 (2892 bp, 15 exons) genes are in the 
background of a rare milder form of osteogenesis imperfecta (type VII, VIII). SureDesign software (Agilent, 
Waldbronn, Germany) was used to design the custom HaloPlex capture assay. We selected all of the coding exons 
of the following genes from RefSeq database and added an extra 10 bases upstream from 3′ end and extra 10 
bases downstream from 5′ end: COL1A1 (100%), COL1A2 (99.05%), CRTAP (100%) and LEPRE1 (100%) with 
99.76% of total coverage. In case of COL1A2, the coverage is 99.05%, because the assay software was not able to 
design capture probes for codons between 234 to 246. The detailed coverage of the targeted genes is shown in 
Supplementary Fig. 1. Total amplicon number was 2036, target size 15.25 kb and the total design was 45.63 kb.
Sequence capture and library preparation. For sequence capture, HaloPlex Target Enrichment System 
Kit, ION (Agilent, Waldbronn, Germany) was used, according to the manufacturer’s instructions. Briefly, in the 
first step, 225 ng (5 ng/μ l) gDNA samples are digested in eight different restriction reactions, each containing two 
restriction enzymes, to create a library of gDNA restriction fragments. The digestion lasted 30 minutes at 37 °C. 
In the second step, the collection of gDNA restriction fragments is hybridized to the HaloPlex probe capture 
library. HaloPlex probes are designed to hybridize selectively to fragments originating from target regions of 
the genome and to direct circularization of the targeted DNA fragments. During the hybridization process, Ion 
Torrent sequencing motifs, including IonXpress barcode sequences, are incorporated into the targeted fragments. 
The hybridization process lasted 3 hours at 54 °C after 10 minutes of denaturing step at 95 °C. In the third, cap-
ture step, the circularized target DNA-HaloPlex probe hybrids, containing biotin, are captured on streptavidin 
beads. HaloPlex Magnetic Beads were added to the DNA-HaloPlex probe hybrids, supernatants were removed 
and Capture Solution was added to the magnetic beads. After 15 minutes of incubation at room temperature, 
the Capture Solution was removed from the beads and Wash Solution was added to the samples and they were 
incubated for 10 minutes at 46 °C, then Wash Solution was discarded. In the next step, DNA ligase is added to the 
capture reaction to close nicks in the circularized HaloPlex probe-target DNA hybrids. The sample tubes were 
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incubated in a thermal cycler at 55 °C for 10 minutes, using a heated lid. When the 10-minute ligation reaction 
period is complete, the following step is to elute the captured DNA libraries with 50 mM NaOH solution. The final 
step of the library preparation is the PCR amplification of the captured target libraries with the following mixture 
per sample: 10 μ l 5X Herculase II Reaction Buffer, 0,4 μ l dNTPs (100 mM), 1 μ l HaloPlex ION Primer 1 (25 μ M), 
1 μ l HaloPlex ION Primer 2 (25 μ M), 0,5 μ l 2 M Acetic acid, 1 μ l Herculase II Fusion DNA Polymerase, 16,1 μ l 
Nuclease-free water followed by 2 minutes incubation at 98 °C, than 21 cycles of 98 °C 30 sec, 60 °C 30 sec and 
72 °C 1 minute with a final 10 minutes of elongation at 72 °C. The amplified target DNA is purified using AMPure 
XP beads (Beckman Coulter). The concentration of the captured libraries was determined by Qubit dsDNA HS 
Assay Kit (ThermoFisher Scientific, Waltham, MA, USA).
Ion Torrent sequencing. The HaloPlex libraries were diluted to 26 pM concentration, then 20 μ l of diluted 
library was added into the emulsion PCR with ISPs using automated template preparation on Ion One Touch 
(ThermoFisher Scientific) instrument with Ion One Touch v2 DL kit (ThermoFisher Scientific). As a result of 
this reaction, amplicons were clonally amplified and bound to the surface of the ISPs. Non-templated beads were 
removed from the solution in an automated enrichment step using Ion One Touch ES instrument (ThermoFisher 
Scientific). ISPs were loaded into Ion 316 chips and the sequencing runs were performed using Ion PGM 200 
Sequencing kit (ThermoFisher Scientific) with 500 flows.
Validation Sanger sequencing. The PCR primers were designed using Primer3Plus (http://primer3plus.
com/) software. Roche FastStart TaqMan Probe Master (Roche, Basel, Switzerland) kit was used to amplify the 
target regions and the PCR program was as follows: 95 °C 10 minutes, 40 cycles of 95 °C 30 sec, 60 °C 30 sec, 
72 °C 45 sec and the final step was 72 °C 5 minutes. PCR products were enzymatically cleaned using ExoSAP 
IT (Affymetrix, Santa Clara, CA, USA) according to the manufacturer. Sanger sequencing was performed 
using BigDye Terminator v3.1 Cycle Sequencing Kit (ThermoFisher Scientific) using an ABI 3130 instrument 
(ThermoFisher Scientific).
Data analysis. Data from the Ion Torrent runs were analyzed using the platform-specific pipeline soft-
ware Torrent Suite v3.2.1 to base-calling, trim adapter and primer sequences, filter out poor quality reads, and 
de-multiplex the reads according to the barcode sequences. Briefly, TMAP algorithm was used to align the reads 
to the reference genome (hg19) and then the variantCaller plugin was selected to run to search for germline var-
iants in the targeted regions. Variants were reviewed and annotated using dbSNP (http://www.ncbi.nlm.nih.gov/
projects/SNP/) and the Osteogenesis Imperfecta Variant Database (oi.gene.le.ac.uk). For variant interpretation 
Ingenuity Variant Analysis Pipeline (Ingenuity Systems Inc., Redwood City, CA, USA) was also used. Called and 
deleterious variants were Sanger sequenced for validation. The Sanger sequences data were investigated using ABI 
Sequence Scanner 1.0 (ThermoFisher Scientific).
Variant classification is based on the current ACMG standards and guidelines 201527.
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